Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.

Advertisement

Related Content

Vical Faced With Failure of Another Vaccine Trial
Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
Vical Joins Forces With Astellas On CMV Vaccine
Vical To Retain Marketing Rights To Allovection-7 In Deal With AnGes

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel